@entity1 with @entity2316 ( @entity740 ) are at a higher risk of developing @entity1187 ( @entity1187 ). However, only a few studies have investigated the separate and joint effects of @entity3918 and @entity740 on the risk of @entity1187 , especially population-based studies under age-, sex- and various @entity65 factor-stratifications. By using a national @entity6 cohort derived from the Taiwan National Health Insurance Research Database, we identified a total of 416,143 @entity3918 and 541,724 non- @entity3918 @entity1 , including 51,208 @entity3918 / @entity740 and 8,894 non- @entity3918 / @entity740 @entity1 , in 2000 who did not have a history of @entity1187 (ICD-9: 410.X, 413.9, 411.1) before 2000. We then prospectively investigated the incidence of @entity1187 by linking to inpatient claims data from 2000 to 2007. A Cox proportional hazard model was used to estimate the relative risk of @entity1187 in individuals with @entity3918 and/or @entity740 under various stratifications.Age- and sex-specific incidence rates were similar between the non- @entity3918 / @entity740 and @entity3918 /non- @entity740 groups, except for female @entity1 under 45 years, in whom @entity3918 was associated with a higher risk of @entity1187 than @entity740 (8.21 vs. 3.82 per 1000 @entity1 -years). In the group aged <45 years, the @entity3918 /non- @entity740 @entity1 were associated with a higher relative hazard of @entity1187 than those in the non- @entity3918 / @entity740 group when compared with the non- @entity3918 /non- @entity740 group ( @entity1 : adjusted hazard ratios [AHR]:1.77; 95% confidence interval [CI]:1.61-1.93 vs. 1.42 [95% CI: 0.73-2.73]; @entity1 1.97 [95% CI: 1.76-2.20] vs. 1.13 [95% CI: 0.36-3.52]). This discrepancy in AHR was reduced with increasing age. The co-existence of @entity3918 and @entity740 further enhanced the AHR in a multiplicative independent manner. A significant age-modification effect was noted in the @entity3918 individuals regardless of their @entity740 status, but not in the non- @entity3918 / @entity740 group. In stratification by various @entity65 factors, @entity6 had a higher risk of @entity1187 than @entity740 in @entity1 with  <=2 selected risk factors, with the exception of the @entity407 and @entity101 subgroup. When all three selected risk factors were included, @entity740 was associated with a higher risk of @entity1187 than @entity3918 (AHR: 1.43 [1.27-1.60] vs. 1.25 [1.22-1.29]). In conclusion, @entity3918 and @entity740 were associated with different levels of risk for @entity1187 according to age, sex and certain @entity65 factors. Strategies aimed at preventing @entity1187 should therefore be individualized according to the presence of @entity3918 , @entity740 and various @entity65 factors.

Separate and joint effects of @entity6 and XXXX on the risk of @entity1187 : a population-based cohort study.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Patient', 'person', 'men'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndrome'] @entity407 :: ('MESH:D006949', 'Disease') :: ['hyperlipidemia'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity2316 :: ('MESH:D003928', 'Disease') :: ['diabetes (DM) and chronic kidney disease'] @entity740 :: ('MESH:D051436', 'Disease') :: ['CKD'] @entity3918 :: ('MESH:D009223', 'Disease') :: ['DM'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular risk']
@entity740 :: (MESH:D051436,Disease) :: ['chronic kidney disease']
